Summit Therapeutics (SMMT) Payables: 2017-2025
Historic Payables for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to $22.2 million.
- Summit Therapeutics' Payables fell 19.84% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.9 million, marking a year-over-year decrease of 60.85%. This contributed to the annual value of $4.6 million for FY2024, which is 73.83% up from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Payables is $22.2 million, which was down 3.21% from $23.0 million recorded in Q2 2025.
- Summit Therapeutics' Payables' 5-year high stood at $103.3 million during Q2 2024, with a 5-year trough of $710,000 in Q1 2023.
- In the last 3 years, Summit Therapeutics' Payables had a median value of $6.4 million in 2024 and averaged $27.3 million.
- Per our database at Business Quant, Summit Therapeutics' Payables tumbled by 89.80% in 2023 and then skyrocketed by 10,370.11% in 2024.
- Over the past 5 years, Summit Therapeutics' Payables (Quarterly) stood at $4.4 million in 2021, then soared by 360.11% to $20.1 million in 2022, then plummeted by 86.75% to $2.7 million in 2023, then soared by 73.83% to $4.6 million in 2024, then dropped by 19.84% to $22.2 million in 2025.
- Its Payables stands at $22.2 million for Q3 2025, versus $23.0 million for Q2 2025 and $5.0 million for Q1 2025.